Novartis faces drug pipeline test with valuation premium in focus

By Bhanvi Satija LONDON, July 20 (Reuters) – Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)